spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Aptar Pharma Completes First Phase of Global Expansion Program to Meet Growing Customer Capacity Needs for Injectable Drug Delivery

Aptar Pharma



Crystal Lake, Illinois, October 31, 2022 - Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that it has delivered the first phase of its previously announced expansion program of approximately $180 million USD to meet growing customer capacity needs for injection system solutions. The multisite, international expansion project began in 2020 and is intended to significantly boost capacity across all product lines, ultimately enabling Aptar Pharma to produce over 10 billion injectable component units annually when completed.



“Our planned expansion program proved timely and was expedited by the arrival of the COVID19 pandemic,” said Gael Touya, President, Aptar Pharma. “The investments we’re making to expand manufacturing capacity and in new, digitalized processes will benefit our customers well into the future.” According to recent market research1,2 , injectables represents around 50% of the pharmaceutical drug development pipeline, with an estimated 40% market share. Between 2016 and 2021, injectables showed the largest drug sales growth of over 10% compound annual growth rate (CAGR 16-21), driven mainly by biologics and the demand for high value solutions, such as coated components like Aptar Pharma’s PremiumCoat® .

Bold New Capabilities

Aptar Pharma’s investment encompasses the expansion and ramping up of Aptar Pharma manufacturing of PremiumCoat® ETFE film-coated components, PremiumFill® enhanced specification solutions, elastomer components and vial stoppers worldwide.

The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint. The first phase of the PremiumCoat® capacity expansion is already operational in Granville, France and includes new ISO7 clean rooms and advanced robotics.

An additional factory in Granville, France will be operational as of early 2024, which leverages the latest technology. US-based manufacturing capabilities will also be operational as of 2024 to better serve the local market. Further manufacturing expansion phases in both the US and France are also included in the program.

A New, State-of-the-Art Manufacturing Facility in Granville, France

The establishment of a second manufacturing facility in Granville, France marks a new milestone in the transformation of Aptar Pharma and paves the way for a step change in capacity and high-tech efficiency. This highly automated factory will significantly increase production capacity to meet growing demand for elastomeric components, including PremiumCoat® solutions for enhanced drug/container compatibility. Partial funding of 13 million Euros for the building and expansion of Aptar Pharma’s European facilities was awarded as part of the French government’s Program of Investments for the Future.

Meeting the Needs of Customers - And the Planet

To meet the ever-increasing market and customer requirements for even higher quality and reliability, Aptar Pharma is expanding its capabilities with robotization, digitalization and new clean rooms. Sustainability is a major consideration in Aptar Pharma’s expansion program, with the implementation of solar power production, water waste management and optimized energy consumption included.

Forging Closer Partnerships With Customers Worldwide

Aptar Pharma’s expansion was designed with customers in mind. By increasing the capacity and capabilities available through its regional manufacturing centers, Aptar Pharma is positioned to bring new levels of agility and responsiveness in order to meet the most demanding injectable customer needs around the world.

“With this program, we’re transforming our organization to offer pharma companies of all sizes enhanced ways to fast-track and derisk their product development,” said Gabriel Zenker, President, Aptar Pharma Injectables. “In doing so, we’re fulfilling our commitment to making Aptar Pharma a first-choice, long-term partner for those seeking sustainable success for their drug development pipelines as part of our mission to shape the future of injectables together with our customers.”

1) https://www.iqvia.com/
2) https://www.pharmacircle.com/info/
phone +33 (0)13 917 2020
email info.pharma@aptar.com
web www.aptar.com/pharma
email 36-38 Rue de la Princesse, 78431 Louveciennes
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

SYDNEY, AUSTRALIA – 06 December 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been established for IMP761, its proprietary preclinical candidate for autoimmune diseases. The 200L scale attained by Northway Biotech, an end-to-end biopharmaceutical contract development and manufacturing organisation (CDMO), will ensure supply of IMP761 for IND-enabling studies and ensuing clinical trials.
More info >>


White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement